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Abstract
Telaprevir and Boceprevir are the first direct acting 
antivirals approved for chronic hepatitis C in combination 
with peg-interferon alfa and ribavirin. Pancytopenia due 
to myelotoxicity caused by these drugs may occur, but 
severe hematological abnormalities or aplastic anemia 
(AA) have not been described. We collected all cases 
of severe pancytopenia observed during triple therapy 
with telaprevir in four Spanish centers since approval 
of the drug in 2011. Among 142 cirrhotic patients 
receiving treatment, 7 cases of severe pancytopenia 
(5%) were identified and three were consistent with the 
diagnosis of AA. Mean age was 59 years, five patients 
had compensated cirrhosis and two patients had 
severe hepatitis C recurrence after liver transplantation. 
Severe pancytopenia was diagnosed a median of 10 
wk after the initiation of therapy. Three patients had 
pre-treatment hematological abnormalities related to 
splenomegaly. In six patients, antiviral treatment was 
interrupted at the onset of hematological abnormalities. 
Two patients died due to septic complications and 
one patient due to acute alveolar hemorrhage. The 
remaining patients recovered. Severe pancytopenia and 
especially AA, are not rare during triple therapy with 
telaprevir in patients with advanced liver disease. Close 
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We describe 7 cases of severe pancytopenia in 
patients receiving antiviral treatment with PR and 
telaprevir, three being consistent with the diagnosis of 
aplastic anemia (AA).
CASE REPORT
Case 1
This patient was a 51-year-old woman with genotype 
1b HCV-related cirrhosis. She had stable neutropenia 
(1500 cells/µl) and thrombocytopenia (74 x 109/l) 
that were likely related to portal hypertension (hepatic 
venous portal pressure gradient (HVPG) of 16 
mmHg). Esophageal varices were not found on upper 
gastrointestinal endoscopy. She had no comorbidities 
and she did not take any medications. Viral load 
(Vl) was undetectable at week 4 of triple therapy 
including telaprevir. At this time, blood analysis 
revealed worsening of neutropenia (1000 cells/µl), 
thrombocytopenia (42 x 109/l) and a decrease of 2.5 
g/dl in hemoglobin (Hb) level, leading to interferon 
and ribavirin dose reduction. One week later, she 
complained of worsening of general condition, 
epistaxis, and mild rash. Blood tests revealed severe 
pancytopenia (Table 1). The patient was admitted to 
hospital; antiviral therapy was immediately interrupted 
and blood and platelet transfusions were administered. 
Despite supportive blood transfusion and granulocyte 
colony-stimulating factor (GCSF) the hematological 
abnormalities did not improve. A bone marrow aspirate 
showed a leucocyte population formed by lymphocytes 
(41%) and normal phenotypic plasma cells (55%) 
with the absence of neutrophils. Bone marrow biopsy 
was compatible with AA (Figures 1 and 2). Other 
acquired causes of bone marrow failure such as 
myelodysplastic syndromes, leukemia, megaloblastic 
anemia, paroxysmal nocturnal hemoglobinuria and viral 
hemophagocytic syndrome were excluded. Due to the 
lack of improvement of hematological parameters and 
the contraindication of bone marrow transplantation, 
cyclosporine was started with no improvement. 
The patient developed pulmonary aspergillosis and 
subsequently presented progressive liver and renal 
failure and died 50 d after admission.
Case 2
This patient was a 56-year-old woman with HCV 
genotype 1a-related cirrhosis that was diagnosed 6 
years earlier by liver biopsy and remained compensated. 
She was on oral therapy for diabetes mellitus. Two 
days after the initiation of triple therapy with telaprevir 
she developed a grade I micropapular rash which was 
successfully treated with topical corticoids and anti-
histamines. At week 4 of therapy she complained of 
fever, odynophagia and cough. Physical examination 
showed an erythematous tonsillitis with candidiasis 
lesions. Blood tests showed a total leukocyte count of 
570 cells/µl with 0% neutrophils, a platelet count of 19 
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monitoring is imperative in this setting to promptly 
detect serious hematological disorders and to prevent 
further complications.
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Core tip: Addition of the new directly acting antivirals, 
Telaprevir and Boceprevir, clearly improved sustained 
virological response rates in patients with chronic 
hepatitis C. However, these combinations have also 
increased the risk of serious adverse events, especially 
in patients with advanced liver fibrosis. We describe 
the development of severe pancytopenia and aplastic 
anemia during triple therapy with telaprevir in patients 
with advanced liver disease (before or after liver 
transplantation). Close monitoring is imperative in 
this setting to promptly detect serious hematological 
disorders and to prevent further complications.
Lens S, Calleja JL, Campillo A, Carrión JA, Broquetas T, Perello 
C, de la Revilla J, Mariño Z, Londoño MC, Sánchez-Tapias 
JM, Urbano-Ispizua Á, Forns X. Aplastic anemia and severe 
pancytopenia during treatment with peg-interferon, ribavirin and 
telaprevir for chronic hepatitis C. World J Gastroenterol 2015; 
21(17): 5421-5426  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v21/i17/5421.htm  DOI: http://dx.doi.
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INTRODUCTION
Addition of the new directly acting antivirals (DAAs), 
Telaprevir and Boceprevir, clearly improved sustained 
virological response (SVR) rates in patients with 
chronic hepatitis C[1-5]. However, these combinations 
also increased the risk of serious adverse events 
(SAEs). One of the most common adverse events 
associated with triple therapy compared to standard 
peg-interferon and ribavirin (PR) regimens is anemia[6]. 
Interferon-related bone marrow suppression and 
ribavirin-related hemolytic anemia are common and 
may lead to dose-reduction, especially in patients 
with baseline cytopenia[7]. Nonetheless, very few 
cases of severe pancytopenia and only one case of 
aplastic anemia related to interferon therapy have 
been reported in patients with chronic hepatitis C virus 
(HCV)[8,9]. Thus, severe hematological disorders appear 
to be anecdotic as a great number of patients have 
been treated with these drugs during the last decades. 
As far as we know, cases of aplastic anemia related 
to telaprevir or boceprevir combination therapy have 
not been reported. Instead, a case of successful triple 
therapy in a patient with severe aplastic anemia has 
been recently reported[10]. 
x 109/l, Hb of 7 g/dl, and 0.1% reticulocytes (Table 1). 
The chest X-ray was normal. The patient was admitted 
to hospital and antiviral therapy was withdrawn. A 
bone marrow biopsy showed marked hypocellularity 
without morphologic abnormalities, consistent with AA. 
Supportive treatment with erythropoietin (EPO), GCSF 
and blood and platelet transfusion was initiated. Oral 
candidiasis due to Candida albicans was successfully 
eradicated. Two months later the patient’s hematological 
abnormalities had fully recovered.
Case 3
This patient was a 67-year-old woman with HCV 
genotype 1a compensated cirrhosis, autoimmune 
hypothyroidism, arterial hypertension, and well 
controlled diabetes mellitus. Concomitant medications 
were metformin, levothyroxine, atenolol and eprosartan. 
Four weeks after initiation of antiviral therapy with 
PR and telaprevir, the Vl was undetectable. There 
was an Hb concentration decrease of 5 g/dl from 
baseline and a blood transfusion was administered at 
this time. Ribavirin dose was adjusted and treatment 
with EPO was initiated. Three weeks later she was 
admitted to the Intensive Care Unit with the diagnosis 
of septic shock requiring vasoactive drug support and 
severe pancytopenia. Antiviral therapy was stopped at 
admission. Methicillin-sensitive Staphylococcus aureus 
was isolated in blood cultures within 48 h and specific 
antibiotic therapy was started (cloxacillin and piperacillin-
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Table 1  Liver function and blood tests at baseline and at the development of severe pancytopenia and final outcome
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 (LT) Case 7 (LT)
Features at baseline
   Hemoglobin (g/dL) 14.3 14.2 12.9 13.5 13.4 13.9 14
   Neutrophils (mm3) 1500 1320 1900 900 3810 2880 1700
   Platelets (mm3) 74000 96000 108000 101000 199000 102000 78000
   ALT (IU/L) 59 77 46 96 77 120 536
   Bilirubin (mg/dL) 1.3 0.93 0.6 1.1 0.5 1.4 1.2
   Albumin (g/dL) 32 47 37 40 45 35 36
   INR 1.1 1.1 1 1 1 1.1 1.28
   Liver stiffness (kPa) 50 10.8 16 11 16.8 14.2 12
   HVPG (mmHg) 16 - - 8.5 - 8.5 -
Child-Pugh score 6 5 5   5 5 6 5
Features at diagnosis of pancytopenia
   Triple therapy (wk) 10 4 7 5 16 16 8
   Hemoglobin (g/dL) 7.5 7 7.8 7.6 7.2 7.9 8.5
   Neutrophils (cells/µL) 400 0 250 200 400 400 300
   Platelets (109/L) 5000 19000 2400 23000 12000 9000 30000
   Reticulocytes (109/L) 0.2% 0.1% 0.6% - < 1% < 1% -
   Bone Marrow Biopsy Yes Yes Yes - - - -
Specific treatment
   Treatment interruption Yes Yes Yes Yes No Yes Yes
   Blood transfusion (units) 14   7 NA 6   20 10   0
   EPO (days of therapy) 30 60 60 6 240 90 30
   GCSF (days of therapy) 30 60 30 6   90 90 45
Outcome Death Recovered Death Death Recovered Recovered Recovered
LT: Liver transplantation; ALT: Alanine aminotransferase; INR: International normalized ratio; HVPG: Hepatic venous pressure gradient; AA: Aplastic 
anemia; EPO: Erythropoietin; GCSF: Granulocyte colony stimulating factor; NA: Not available.
Figure 1  Bone marrow section showing a marked reduction in hemopoietic 
precursors which are mainly replaced by fat (hematoxylin eosin staining, 
magnification × 200).
Figure 2  Hematopoietic cells replaced by fat vacuoles and a variable 
inflammatory infiltrate composed of lymphocytes and plasma cells 
is observed. No megakaryocytes are present (hematoxylin eosin staining, 
magnification × 400).
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orthotopic liver transplantation (lT) 24 mo before 
due to advanced HCV genotype 1b-related cirrhosis. 
Immunosuppressive therapy consisted of tacrolimus 
monotherapy with stable levels and no dose modi-
fications during the previous months. He was also 
taking statins for hypercholesterolemia. No other 
comorbidities were present and the patient received 
no other medications. The patient developed HCV 
recurrence with severe liver injury at 21 mo after lT, 
as indicated by cholestasis, high Vl (4 x 106 IU/ml) 
and increasing transient elastography values (14 kPa). 
The HVPG value was 8.5 mmHg, and a transjugular 
liver biopsy showed necroinflammatory activity and 
periportal fibrosis (F2) on the METAVIR scale, but 
no signs of rejection. At week 16 of triple therapy 
with telaprevir, 4 wk after telaprevir was stopped he 
presented with grade 3 anemia, neutropenia and 
severe thrombocytopenia. Antiviral therapy was 
withdrawn and blood and platelet transfusions were 
administered (Table 1). Supportive care with EPO and 
GCSF was maintained for a further 3 months. The 
patient achieved a SVR despite early discontinuation 
of antivirals, and he also recovered from the hema-
tological abnormalities.
Case 7
This patient was a 63-year-old woman whose liver 
histology showed advanced fibrosis (F3) 18 mo after 
lT. She had a genotype 1b infection, Vl was 2 x 106 
IU/l, and AlT and AST values were 235 and 536 
IU/l, respectively. Immunosuppressive treatment 
consisted of tacrolimus and low-dose prednisone. 
She had developed diabetes mellitus after lT and was 
receiving insulin therapy. When triple therapy with PR 
and telaprevir was initiated, she presented a stable 
mild thrombocytopenia of 78 x 109/l. At week 4 of 
therapy, there was a marked decrease in neutrophils 
(500 cells/µl) along with anemia (Hb 10 g/l) and a 
further decrease in platelet count (50 x 109/l). The 
Vl was undetectable. Doses of PR were adjusted 
and supplementary therapy with EPO and GCSF was 
given. Despite these measures, the neutrophil count 
continued to decrease and antiviral therapy was 
interrupted at week 6 (Table 1). One month later, the 
hematological abnormalities disappeared and this was 
followed by a SVR in spite of early discontinuation of 
therapy.
DISCUSSION
The approval of first generation protease inhibitors 
(PIs), boceprevir and telaprevir, has been a major step 
forward in the treatment of chronic hepatitis C[1,2,4,5]. 
Beyond the efficacy results, PIs-based regimens in 
patients with compensated cirrhosis may be associated 
with SAEs such as severe infections (4%-6%), clinical 
decompensation (3%-4%) and even death. These 
events were not reported in the registration trials, 
possibly because patients included in these studies 
tazobactam). Despite extensive investigations, the 
source of the infection was not identified. Pancytopenia 
progressively worsened (Table 1). The patient de-
veloped renal failure requiring hemodialysis as well as 
liver failure with bilirubin increasing up to 18 mg/dl 
and ascitic decompensation. The patient presented a 
multiorgan invasive zygomycosis and died one month 
after admission. Necropsy confirmed AA with severe 
hypocellularity in the bone marrow. 
Case 4
This patient was a 62-year-old woman with HCV 
genotype 1b-related cirrhosis. She had durable 
neutropenia (about 900 cells/µl) possibly related to 
hypersplenism due to portal hypertension (HVPG 8 
mmHg). Upper gastrointestinal endoscopy detected 
a small esophageal varicose vein. She did not have 
comorbidities and did not take medications. Vl was 
undetectable at week four of triple therapy with 
telaprevir. At this point, total neutrophil and platelet 
counts were 700 cells/µl and 47 x 109/l, respectively. 
One week later she was admitted to the hospital 
due to fever and chills lasting 48 h. The chest X-ray 
showed a right inferior lobe pneumonia and broad 
spectrum coverage antibiotic therapy was started. 
Blood tests disclosed severe pancytopenia (Table 
1). Antiviral therapy was interrupted and supportive 
treatment with red blood cell and platelet transfusion 
was initiated. Seventy-two hours after admission, she 
suddenly presented a massive hemoptysis with alveolar 
hemorrhage. Despite orotracheal intubation and 
mechanical ventilation the patient suffered a cardiac 
arrest and did not recover. Necropsy was not performed.
Case 5
This patient was a 68-year-old woman with HCV 
genotype 1b-related cirrhosis and cryoglobulinemia. 
She had no comorbidities and she did not take any 
medications. Vl was undetectable at week 4 of triple 
therapy with telaprevir. The patient was hospitalized 
at week 8 due to acute pyelonephritis caused by 
Escherichia coli. The infection resolved after 2 wk of 
intravenous antibiotic therapy. Due to grade 3 anemia, 
the patient required a blood transfusion at week 12, 
and treatment with EPO and ribavirin dose reduction 
was required at this time. The patient completed 
12 wk of telaprevir therapy and then continued on 
treatment with PR. During the following 4 wk, the 
patient developed severe pancytopenia (Table 1) 
despite supportive treatment with transfusions, EPO 
and GCSF administration. Reticulocyte count was < 1% 
x 109/l. Other causes of pancytopenia were ruled out. 
The patient continued on antiviral therapy until week 
48, at reduced doses of PR. She achieved a sustained 
virological response (SVR) and is currently recovering 
from the hematological disorder.
Case 6
This patient was a 51-year-old man who underwent 
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were mainly very well compensated cirrhotics without 
significant portal hypertension. Indeed, a low platelet 
count was an exclusion criterion (< 90 × 109/l for 
telaprevir and < 100 × 109/l for boceprevir) in these 
trials. The results of triple therapy in cirrhotic patients 
demonstrated that a low platelet count (< 100 × 
109/l) and low serum albumin (< 35 g/l) were strong 
predictors of severe complications. Importantly, the 
risk of severe complications was 44% in patients with 
both factors as compared to 3.4% in patients with 
normal platelet and albumin values[11]. 
The mechanism of hematological toxicity during 
triple therapy is still not completely understood, but 
is probably related to the concomitant administration 
of all three drugs. Interferon results in bone marrow 
suppression and ribavirin leads to hemolysis, while PIs 
may cause direct bone marrow toxicity (as suggested 
in a few reports in the setting of HIV infection[12,13]) in 
patients with portal hypertension or advanced cirrhosis. 
Finally, the risk of hematological abnormalities could 
also be influenced by genetic factors[14].
Severe AA is defined by a bone marrow cellu-
larity < 25%, or 25%-50% with < 30% residual 
hematopoietic cells, and at least 2 of the following 
factors: neutrophils < 0.5 cells/µl, platelets < 20 × 
109/l and low reticulocyte count. The overall incidence 
of this disease is low, as it is estimated to occur 
in only 2-4 million people per year[15]. Antibiotics, 
anti-inflammatory drugs and anticonvulsants are 
among the currently licensed drugs which have been 
associated with AA[16].
Severe bone marrow hypocellularity related to 
interferon administration has been reported not only 
in the setting of HCV infection[8,9]. However, taking into 
account the huge number of patients treated with this 
drug worldwide, the incidence of this adverse event 
appears to be extremely low. Indeed, in our center, 
of 1700 HCV patients treated with PR therapy in the 
last decades, there have been no cases of AA. The 
only reported case in the literature is a non-cirrhotic 
46-year-old man who developed AA 4 mo after the 
initiation of PR therapy and had a fatal outcome 
despite bone marrow transplantation[8]. 
Among 142 cirrhotic patients receiving treatment 
in four Spanish centers since the approval of triple 
therapy in 2011, 7 cases of severe pancytopenia (5%) 
were identified and three had diagnostic features 
consistent with AA (2%). The mean age of these 
patients was was 59 years, 5 were Child A cirrhotics 
and two had severe HCV recurrence after lT. The 
mean liver stiffness value was 18 kPa, three patients 
had portal hypertension (range: 8.5-16 mmHg) and 
3 patients had abnormal pre-treatment hematological 
values possibly related to splenomegaly (Table 1). All 
patients were closely monitored from the beginning of 
treatment (at least biweekly) and PR dose adjustments 
were made depending on hematological values. The 
diagnosis of severe pancytopenia was made a median 
of 10 wk after telaprevir initiation and antiviral therapy 
was interrupted at the time of this diagnosis in all 
but one patient (case 5). At diagnosis, the MeDRA 
classification of adverse events was > 3 in all cases 
(severe or medically significant, but not immediately 
life-threatening with hospitalization indicated).
Importantly, when these patients were offered triple 
therapy, data on predictive factors associated with 
severe complications were not yet available. However, 
when retrospectively analysing if these patients would 
have been candidates for antiviral treatment with 
telaprevir, only case 1 would have been excluded 
due to the presence of both thrombocytopenia and 
hypoalbuminemia (case 1). 
Three patients had diagnostic features of AA 
(cases 1-3). In case 3, AA developed during septic 
shock and antibiotic treatment, thus, an influence 
on the development of bone marrow toxicity cannot 
be disregarded. In the remaining patients, other 
potential causes of AA were excluded by anamnesis 
and laboratory tests. Bone marrow biopsy histology 
revealed hypocellularity and excluded an infiltrative 
disease (Figures 1 and 2). 
Despite all patients being diagnosed very early and 
receiving support in referral centers; two patients had 
septic complications and died due to multiorgan failure 
and one patient had a massive hemoptysis and did not 
recover despite vital support measures. 
In conclusion, hematological adverse events 
are frequent during antiviral therapy with protease 
inhibitors in patients with chronic hepatitis C. A 
specialized center with expertise should be contacted 
as early as possible in order to initiate measures aimed 
at obtaining the best supportive care and exclude 
other possible causes of pancytopenia. Although AA 
is a rare condition, it has now been diagnosed during 
triple therapy with telaprevir in patients with advanced 
liver disease. Close monitoring of hematological 
tests is advised during treatment and therapy should 
be promptly interrupted in the case of a decrease 
in the three hematopoietic series to prevent the 
establishment of AA and its complications.
COMMENTS
Case characteristics
Seven cases of severe pancytopenia were identified and three had diagnostic 
features consistent with aplastic anemia (AA) during triple therapy with 
telaprevir. The mean age of these patients was 59 years, 5 were Child A 
cirrhotics and two had severe hepatitis C virus (HCV) recurrence after liver 
transplantation. The mean liver stiffness value was 18 kPa, and three patients 
had portal hypertension (range: 8.5-16 mmHg). 
Clinical diagnosis
The diagnosis of severe pancytopenia was made a median of 10 wk after 
telaprevir initiation.
Differential diagnosis
Other causes of hematological disorders were excluded (drug toxicity, vitamin 
deficiency, bone marrow infiltration, malignancy). 
Laboratory diagnosis
Severe AA was defined by a bone marrow cellularity < 25%, or 25%-50% with 
< 30% residual haematopoietic cells, and at least 2 of the following factors: 
neutrophils < 0.5 cells/µl, platelets < 20 × 109/L and low reticulocyte count. 
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The remaining cases had severe pancytopenia (hemoglobin levels < 10 g/dl, 
neutrophils < 0.75 cells/µl and platelets < 50 × 109/L).
Pathological diagnosis
Bone marrow biopsy histology revealed hypocellularity and excluded an 
infiltrative disease.
Treatment
Early discontinuation of antiviral therapy after AA diagnosis. Supportive care 
with G-CSF and blood and platelet transfusions was administered. One patient 
received cyclosporine. 
Related reports
Interferon-related bone marrow suppression and ribavirin-related hemolytic 
anemia are common and may lead to dose-reduction, especially in patients with 
baseline cytopenia. Nonetheless, very few cases of severe pancytopenia and 
only one case of AA related to interferon therapy have been reported in patients 
with chronic hepatitis C infection.
Term explanation 
The addition of a protease inhibitor to antiviral treatment may induce bone-
marrow toxicity, especially in patients with advanced liver disease.
Experiences and lessons
In conclusion, hematological adverse events are frequent during antiviral 
therapy with protease inhibitors in chronic hepatitis C. A specialized center 
with expertise should be contacted as soon as possible in order to initiate 
measures aimed at obtaining the best supportive care and to exclude other 
possible causes of pancytopenia. Although AA is a rare condition, it has now 
been diagnosed during triple therapy with telaprevir in patients with advanced 
liver disease. Close monitoring of hematological tests is advised during 
treatment and therapy should be promptly interrupted in the case of a decrease 
in the three hematopoietic series to prevent the establishment of AA and its 
complications.
Peer-review
The authors presents seven cases of severe pancytopenia (three of them 
with AA) occurred in patients with HCV related cirrhosis during triple therapy 
(peginterferon + ribavirin + telaprevir). The adverse effects associated with triple 
therapy are common and well-known.
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